摘要
目的评价联用来曲唑治疗晚期及绝经妇女乳腺癌的效果。方法检索近10年PubMed、Cochrane Data-base of Systematic Reviews、EMbase、中国知网、万方数据库关于来曲唑治疗乳腺癌的随机对照研究(RCT),同时筛检纳入文献的参考文献,对纳入研究的方法学进行评价。研究者对文献质量进行严格评价和资料提取,对符合质量标准的文献用Review Manager 5.0软件进行Meta分析。结果共5篇文献9398例患者纳入研究,其中治疗组(使用来曲唑)4699例,对照组(使用他莫西芬)4699例,基线资料可比。Meta分析结果示治疗组远处转移、控制肿瘤面积、不良反应与对照组比较差异均有统计学意义[(RR=0.82,95%CI(0.69,0.97);RR=1.61,95%CI(1.46,1.77);RR=0.87,95%CI(0.78,0.98)]。结论与传统的治疗方案比较,来曲唑可显著提高乳腺癌患者的治疗效果,且不良反应少。
Objective To evaluate the efficacy of Letrozole treatment in advanced breast cancer and postmenopausal breast cancer. Methods We searched PubMed, Cochrane Database of Systematic Reviews, EMbase, CNKI, WANFANG Data- base about Letrozole treatment of breast cancer of randomized study （RCT） , and screened our literature references published during the past 10 years, and evaluated them using Meta analysis with Review Manager 5.0 system. Results 5 literatures with a total of 9398 cases were included in the study; Treatment group （Letrozole, 4699 cases） and control group （Tamoxifen, 4699 cases）. Mcta-analysis results showed that there were significant differences in distant metastases, control of tumor size, adverse reactions between the two groups [（RR --0.82, 95%CI （0.69, 0.97）; RR =1.61, 95%CI （1.46, 1.77）; RR =0.87, 95% CI （0. 78, 0.98）]. Conclusion Compared to conventional treatment, Letrozole can significantly improve the efficacy of treatment in breast cancer patients.
出处
《临床误诊误治》
2012年第6期68-71,共4页
Clinical Misdiagnosis & Mistherapy
